JP2015529236A - ヘテロ二量体免疫グロブリンの精製 - Google Patents

ヘテロ二量体免疫グロブリンの精製 Download PDF

Info

Publication number
JP2015529236A
JP2015529236A JP2015532465A JP2015532465A JP2015529236A JP 2015529236 A JP2015529236 A JP 2015529236A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A JP2015529236 A JP 2015529236A
Authority
JP
Japan
Prior art keywords
immunoglobulin
region
fragment
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015532465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529236A5 (enExample
Inventor
ブレイン，スタニスラス
コンペル，ファブリツィオ
オリエル，ロメイン
ワスマン，ポール
Original Assignee
グレンマーク ファーマシューティカルズ， エセ．アー．
グレンマーク ファーマシューティカルズ， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク ファーマシューティカルズ， エセ．アー．, グレンマーク ファーマシューティカルズ， エセ．アー． filed Critical グレンマーク ファーマシューティカルズ， エセ．アー．
Publication of JP2015529236A publication Critical patent/JP2015529236A/ja
Publication of JP2015529236A5 publication Critical patent/JP2015529236A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015532465A 2012-09-25 2013-09-25 ヘテロ二量体免疫グロブリンの精製 Pending JP2015529236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
US61/705,278 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018020450A Division JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Division JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製

Publications (2)

Publication Number Publication Date
JP2015529236A true JP2015529236A (ja) 2015-10-05
JP2015529236A5 JP2015529236A5 (enExample) 2016-11-10

Family

ID=49237223

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015532465A Pending JP2015529236A (ja) 2012-09-25 2013-09-25 ヘテロ二量体免疫グロブリンの精製
JP2018020450A Pending JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Expired - Fee Related JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製
JP2020036853A Ceased JP2020105203A (ja) 2012-09-25 2020-03-04 ヘテロ二量体免疫グロブリンの精製
JP2022092045A Pending JP2022116326A (ja) 2012-09-25 2022-06-07 ヘテロ二量体免疫グロブリンの精製

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018020450A Pending JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Expired - Fee Related JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製
JP2020036853A Ceased JP2020105203A (ja) 2012-09-25 2020-03-04 ヘテロ二量体免疫グロブリンの精製
JP2022092045A Pending JP2022116326A (ja) 2012-09-25 2022-06-07 ヘテロ二量体免疫グロブリンの精製

Country Status (11)

Country Link
US (2) US20150239991A1 (enExample)
EP (2) EP2900696A1 (enExample)
JP (5) JP2015529236A (enExample)
KR (1) KR20150076172A (enExample)
CN (1) CN104968685A (enExample)
AU (2) AU2013322710A1 (enExample)
CA (2) CA2886036A1 (enExample)
HK (1) HK1215950A1 (enExample)
IL (2) IL237872B (enExample)
IN (1) IN2015MN00139A (enExample)
WO (1) WO2014049003A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105203A (ja) * 2012-09-25 2020-07-09 イクノス サイエンシズ エスエー ヘテロ二量体免疫グロブリンの精製
JP2021528435A (ja) * 2018-06-22 2021-10-21 ゲンマブ エー／エス ２つ以上の異なる抗体の制御された混合物を産生するための方法

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
DK2417156T3 (en) 2009-04-07 2015-03-02 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
NZ701769A (en) 2009-09-16 2016-06-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
PL2992012T3 (pl) 2013-04-29 2019-12-31 F. Hoffmann-La Roche Ag Zmodyfikowane ludzkie przeciwciała wiążące FcRn i sposoby ich zastosowania
CA2922979A1 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
EP3842455A1 (en) * 2014-01-15 2021-06-30 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
KR20230022270A (ko) 2014-03-28 2023-02-14 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
WO2016016299A1 (en) * 2014-07-29 2016-02-04 F. Hoffmann-La Roche Ag Multispecific antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
ES2973885T3 (es) 2015-07-09 2024-06-24 Genmab As Anticuerpos biespecíficos y multiespecíficos y método para aislarlos
AU2016347058B2 (en) 2015-10-25 2023-11-09 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
JP7195929B2 (ja) * 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
EP4257193B1 (en) 2016-04-13 2025-12-31 Sanofi TRISPECIFIC AND/OR TRIVALENT LINKING PROTEINS
CN109071635B (zh) * 2016-05-02 2023-09-01 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
SG11201901307VA (en) 2016-09-29 2019-03-28 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
CN109963876B (zh) 2016-11-18 2023-11-14 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
CN110770255B (zh) 2017-04-11 2025-07-01 因荷布瑞克斯生物科学公司 具有受限cd3结合的多特异性多肽构建体及其使用方法
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3769083A1 (en) 2018-03-21 2021-01-27 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
SG11202009804RA (en) 2018-04-11 2020-11-27 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
FR3080621B1 (fr) * 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
TW202028246A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3單域抗體及其治療性組合物
CA3115285A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
TWI863932B (zh) 2018-10-11 2024-12-01 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
EP4141025A4 (en) * 2019-12-26 2024-04-24 ABL Bio, Inc. Method for purifying biologically active peptide by using protein a affinity chromatography
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
WO2022077006A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法
JP2023092810A (ja) * 2021-12-22 2023-07-04 国立大学法人東京農工大学 変異抗体、変異抗体の製造方法
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
MA71622A (fr) 2022-07-29 2025-05-30 Alector Llc Domaines de liaison à l'antigène cd98hc et leurs utilisations
WO2024050493A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025087386A1 (zh) * 2023-10-25 2025-05-01 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
JP2012504403A (ja) * 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
ES2431940T3 (es) 2007-02-16 2013-11-28 Merrimack Pharmaceuticals, Inc. Anticuerpos contra la ERBB3 y usos de los mismos
PL2235064T3 (pl) 2008-01-07 2016-06-30 Amgen Inc Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych
EA201190132A1 (ru) 2009-02-23 2013-01-30 Гленмарк Фармасьютикалс С.А. Гуманизированные антитела, связывающиеся с cd19, и их применение
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
EP4477668A3 (en) * 2010-04-20 2025-03-19 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2688909A2 (en) 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
WO2013060867A2 (en) * 2011-10-27 2013-05-02 Genmab A/S Production of heterodimeric proteins
US20150088787A1 (en) 2012-03-06 2015-03-26 Foss Analytical Ab Method, software and graphical user interface for forming a prediction model for chemometric analysis
JP6273219B2 (ja) 2012-03-13 2018-01-31 ノビミューン エスアー 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
JP2008543881A (ja) * 2005-06-17 2008-12-04 エラン ファーマ インターナショナル リミテッド 抗Ａβ抗体を精製する方法
JP2012504403A (ja) * 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 201, JPN5015009939, 1997, pages 25 - 34, ISSN: 0003611945 *
STRUCTURE, vol. 3, no. 3, JPN5015009936, 1995, pages 265 - 278, ISSN: 0003611944 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105203A (ja) * 2012-09-25 2020-07-09 イクノス サイエンシズ エスエー ヘテロ二量体免疫グロブリンの精製
JP2021528435A (ja) * 2018-06-22 2021-10-21 ゲンマブ エー／エス ２つ以上の異なる抗体の制御された混合物を産生するための方法

Also Published As

Publication number Publication date
IL237872A0 (en) 2015-05-31
AU2013322710A1 (en) 2015-04-16
WO2014049003A1 (en) 2014-04-03
JP2020105203A (ja) 2020-07-09
HK1215950A1 (zh) 2016-09-30
US20150239991A1 (en) 2015-08-27
JP2019073512A (ja) 2019-05-16
AU2013322710A2 (en) 2015-05-07
EP2900696A1 (en) 2015-08-05
JP6856610B2 (ja) 2021-04-07
AU2018204314A1 (en) 2018-07-05
KR20150076172A (ko) 2015-07-06
IL269207B (en) 2022-02-01
EP3401337A1 (en) 2018-11-14
JP2022116326A (ja) 2022-08-09
CN104968685A (zh) 2015-10-07
JP2018104444A (ja) 2018-07-05
IN2015MN00139A (enExample) 2015-10-16
IL269207A (en) 2019-11-28
IL237872B (en) 2019-09-26
AU2018204314B2 (en) 2020-05-14
CA3061557A1 (en) 2014-04-03
CA2886036A1 (en) 2014-04-03
US20200010568A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
AU2019257534B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
JP2018501297A (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
HK1227904A (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HK1227904A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160921

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731